alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 293 studies with an author at University of Toronto (CA) (page 3 of 12) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of these 293 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Annual Wellness Visits and Early Dementia Diagnosis Among Medicare Beneficiaries

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA Network Open 2024-10-01

These findings indicate that AWV recipients had a timelier first MCI diagnosis than those who did not receive an AWV, but first ADRD diagnosis differed little. 5 key findings →

Design: cohort Participants: 549,516 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome

✓ Peer-reviewed alzhub usefulness score 66 out of 100. JAMA neurology 2023-05-01

Of 386 participants, 199 (52%) were female, and the mean (SD) age was 68 (8) years. 3 key findings →

Design: cohort study Participants: 113 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2007-09-10

No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia. 5 key findings →

Participants: 103 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts

✓ Peer-reviewed alzhub usefulness score 66 out of 100. The Lancet. Neurology 2017-06-16

Cognitive decline is a debilitating manifestation of disease progression in Parkinson's disease. 4 key findings →

Design: longitudinal study Participants: 3,200 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Annals of neurology 2022-10-13

In DIAD, solanezumab was not associated with ARIA. 5 key findings →

Design: cross-sectional Participants: 52 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Acta neuropathologica 2021-01-05

The category of neocortical LP according to the LPC system was associated with a 5.9 OR (p < 0.0001) of dementia in the 134 NBTR cases and a 3.14 OR (p = 0.0001) in the 202 UPBB cases. 2 key findings →

Participants: 202 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review

✓ Peer-reviewed alzhub usefulness score 65 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2016-04-01

DLB becomes more common with increasing age and accounts for about 5% of all dementia cases in older populations. 1 key finding →

Participants: 1,000 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of ω-3 fatty acids on cognitive performance: a meta-analysis

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Neurobiology of aging 2012-02-03

Higher intake of omega-3 fatty acids (n-3 FAs) is associated with a reduced risk of Alzheimer's disease (AD) and milder forms of cognitive impairment (e.g. cognitive impairment no dementia [CIND]); however, findings from interventional trials are inconsistent. 4 key findings →

Design: meta-analysis Participants: 934 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep

✓ Peer-reviewed alzhub usefulness score 64 out of 100. JAMA neurology 2013-12-01

Better sleep consolidation attenuates the effect of APOE genotype on incident AD and development of neurofibrillary tangle pathology. 2 key findings →

Design: cohort study Participants: 698 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Comparison of phenomic profiles in the All of Us Research Program against the US general population and the UK Biobank

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Journal of the American Medical Informatics Association : JAMIA 2024-04-01

Knowledge gained from cohort studies has dramatically advanced both public and precision health. 4 key findings →

Design: cohort study Participants: 254 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of clinical psychopharmacology 2008-06-01

Apathy is a common behavioral symptom of Alzheimer's disease (AD), being present in up to 70% of patients. 4 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neuron 2011-09-21

The chromosome 9p21 amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) locus contains one of the last major unidentified autosomal-dominant genes underlying these common neurodegenerative diseases. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed